Wall Street Prep – Biotech Sum of the Parts Valuation

About Course:What You Will LearnMarket size and model potential revenue for a therapeutic asset in clinical developmentRoad-map the path to commercialization for a biotech through the FDA approval processApply the appropriate “probability of success”” to a clinical-stage pre-revenue biotech companyApply key assumptions and tie together a long-range forecast of multiple products with a DCF analysisBiotech Sum of the Parts ValuationBiotech SOTP welcomeBiotech SOTP introductionCourse DownloadsOverview of a sum of the parts valuationMajor building blocks for a biotech SOTPModel assumptions dashboardBiotech company lifecycleIdentify peak revenue opportunityTherapeutic areas overviewProduct launch timing and uptake curvePatent life and loss of exclusivityRoad to commercializationFDA clinical trialsBuilding a commercial infrastructureCompleting the SOTPProbability of successBuild out one part of the SOTP (Product #1)Finalizing the valuation modelValuation sensitivitiesExample: Blueprint Medicines CorpBiotech SOTP Course Review